{"id":745322,"date":"2016-10-08T01:15:00","date_gmt":"2016-10-08T01:15:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-in-advanced-urothelial-cancer-demonstrate-overall-response-rate-of-24-percent-in-cisplatin-ineligible-patients\/"},"modified":"2025-11-07T01:25:38","modified_gmt":"2025-11-07T06:25:38","slug":"new-keytruda-pembrolizumab-data-in-advanced-urothelial-cancer-demonstrate-overall-response-rate-of-24-percent-in-cisplatin-ineligible-patients","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-in-advanced-urothelial-cancer-demonstrate-overall-response-rate-of-24-percent-in-cisplatin-ineligible-patients\/","title":{"rendered":"New KEYTRUDA\u00ae (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients"},"content":{"rendered":"<p class=\"bwalignc\">       Results from Interim Analysis of Phase 2 KEYNOTE-052 Study to be        Presented at ESMO 2016 Congress and Highlighted in ESMO Press Program     <\/p>\n<p class=\"bwalignc\">       First Presentation of Data Investigating KEYTRUDA in the Front Line        Treatment of Bladder Cancer     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced positive findings from the phase 2 KEYNOTE-052 study<br \/>\n      investigating the use of KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab), the<br \/>\n      company\u2019s anti-PD-1 therapy, in previously untreated patients with<br \/>\n      unresectable (inoperable) or metastatic urothelial cancer who are<br \/>\n      ineligible for cisplatin-based therapy. Data presented at the ESMO 2016<br \/>\n      Congress, the annual meeting of the European Society for Medical<br \/>\n      Oncology, showed an overall response rate (ORR) of 24 percent (n=24\/100)<br \/>\n      (95% CI, 16-34) in the total study population, which included patients<br \/>\n      with and without PD-L1 expression.\n    <\/p>\n<p>\n      \u201cWe have a growing body of evidence of KEYTRUDA\u2019s activity in a range of<br \/>\n      cancers and treatment settings including the first-line treatment of<br \/>\n      patients with advanced urothelial cancer who will not tolerate<br \/>\n      cisplatin-based therapy,\u201d said Dr. Roger Dansey, senior vice president,<br \/>\n      oncology late-stage development, Merck Research Laboratories.\n    <\/p>\n<p>\n      The KEYTRUDA clinical development program includes more than 30 tumor<br \/>\n      types in more than 350 clinical studies, including more than 100 trials<br \/>\n      that combine KEYTRUDA with other cancer treatments. Merck has the<br \/>\n      largest immuno-oncology clinical development program in bladder cancer<br \/>\n      with 27 trials involving KEYTRUDA, including four registration-enabling<br \/>\n      studies currently underway.\n    <\/p>\n<p>\n      \u201cThere have been very few advancements in the treatment of bladder<br \/>\n      cancer in the past several decades, and patients with urothelial cancer<br \/>\n      who are ineligible for cisplatin-based therapy are in significant need<br \/>\n      of new approaches to care,\u201d said Dr. Dean F. Bajorin, study investigator<br \/>\n      and medical oncologist at Memorial Sloan Kettering Cancer Center. \u201cThese<br \/>\n      data are exciting and demonstrate the potential for an anti-PD-1<br \/>\n      therapy, such as pembrolizumab, to address the unmet treatment need that<br \/>\n      exists today for cisplatin-ineligible patients with this type of<br \/>\n      urothelial cancer.\u201d\n    <\/p>\n<p>\n      Findings from KEYNOTE-052 are being presented at the ESMO 2016 Congress<br \/>\n      by Dr. Arjun V. Balar, medical oncologist and assistant professor of<br \/>\n      medicine at the Perlmutter Cancer Center at NYU Langone Medical Center,<br \/>\n      on Oct. 8 from 9:30 \u2013 9:45 a.m. CEST (Abstract: # LBA32_PR) and are<br \/>\n      featured in the official ESMO press program.\n    <\/p>\n<p>\n      <b>Additional Findings from KEYNOTE-052<\/b>\n    <\/p>\n<p>\n      KEYNOTE-052 is an open-label, phase 2 study evaluating KEYTRUDA<br \/>\n      (pembrolizumab) (200 mg every three weeks) monotherapy as a first-line<br \/>\n      treatment in an estimated 350 patients with unresectable (inoperable) or<br \/>\n      metastatic urothelial cancer (a type of bladder cancer) who are<br \/>\n      ineligible for cisplatin-based therapy. The primary endpoints include<br \/>\n      ORR in all patients enrolled in the study (total study population) and<br \/>\n      in patients with PD-L1 positive tumors (expression of one percent or<br \/>\n      more). Secondary endpoints include duration of response,<br \/>\n      progression-free survival (PFS), and overall survival (OS). Tumor<br \/>\n      response was measured according to RECIST (Response Evaluation Criteria<br \/>\n      in Solid Tumors) v1.1 as assessed by blinded independent central review.\n    <\/p>\n<p>\n      Findings presented at the ESMO 2016 Congress are from the planned<br \/>\n      interim analysis of the first 100 patients, which was intended to<br \/>\n      evaluate ORR and determine the PD-L1-high expression cut-point as<br \/>\n      examined by expression in tumor and immune cells. Forty-five percent of<br \/>\n      patients (n=45\/100) had an ECOG (Eastern Cooperative Oncology Group)<br \/>\n      Performance Status (PS) score of two, 30 percent (n=30\/100) had a PS<br \/>\n      score of one, and 24 percent (n=24\/100) had a PS score of zero.\n    <\/p>\n<p>\n      In the total study population, ORR was 24 percent (n=24\/100) (95% CI,<br \/>\n      16-34) with a complete response rate of six percent (n=6\/100) (95% CI,<br \/>\n      2-13). Review of the outcomes based on PD-L1 expression showed that in<br \/>\n      patients with PD-L1 expression of less than one percent, ORR was 18<br \/>\n      percent (n=6\/33) (95% CI, 7-36) with a complete response rate of three<br \/>\n      percent (n=1\/33) (95% CI, 0.1-16); in patients with PD-L1 expression<br \/>\n      greater than or equal to one percent and less than 10 percent, ORR was<br \/>\n      15 percent (n=5\/33) (95% CI, 5-32) with no complete responses; and, in<br \/>\n      patients expressing PD-L1 at levels equal to or greater than 10 percent,<br \/>\n      ORR was 37 percent (n=11\/30) (95% CI, 20-56) with a complete response<br \/>\n      rate of 13 percent (n=4\/30) (95% CI, 4-31). Among the 24 percent of<br \/>\n      patients in the total study population who were responding to treatment,<br \/>\n      the median duration of response had not been reached (range 1.4+ to 9.8+<br \/>\n      months), with 83 percent of patients (n=20\/24) having responses of six<br \/>\n      months or longer.\n    <\/p>\n<p>\n      The safety profile of KEYTRUDA (pembrolizumab) was consistent with that<br \/>\n      observed in previously reported KEYTRUDA studies. The treatment-related<br \/>\n      adverse events observed in this trial (any grade occurring in five<br \/>\n      percent or more of patients) were fatigue (n=14), pruritus (n=12),<br \/>\n      pyrexia (n=8), decreased appetite (n=7), diarrhea (n=7), rash (n=7),<br \/>\n      chills (n=6), hypothyroidism (n=6), and nausea (n=6). Grade 3-4<br \/>\n      treatment-related adverse events observed (occurring in 2 or more<br \/>\n      patients) were fatigue (n=4), muscle spasms (n=2), decreased appetite<br \/>\n      (n=1), and diarrhea (n=1). Immune-mediated adverse events of Grade 3-4<br \/>\n      were nephritis (n=1) and pneumonitis (n=2). Five patients discontinued<br \/>\n      due to a treatment-related adverse event; there were no<br \/>\n      treatment-related deaths.\n    <\/p>\n<p>\n      <b>About Bladder Cancer<\/b>\n    <\/p>\n<p>\n      Bladder cancer begins when cells in the urinary bladder start to grow<br \/>\n      uncontrollably. As more cancer cells develop, they can form a tumor and<br \/>\n      spread to other areas of the body. Urothelial carcinoma, the most common<br \/>\n      type of bladder cancer, starts in the urothelial cells that line the<br \/>\n      inside of the bladder. In 2012, approximately 430,000 people worldwide<br \/>\n      were diagnosed with bladder cancer and 165,000 died from the disease.<br \/>\n      The incidence of bladder cancer is elevated in North America, Europe,<br \/>\n      North Africa, the Middle East, Australia and New Zealand.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both<br \/>\n      tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes<br \/>\n      every three weeks for the approved indications. KEYTRUDA for injection<br \/>\n      is supplied in a 100 mg single use vial.\n    <\/p>\n<p>\n      <b>KEYTRUDA (pembrolizumab)<\/b> <b>Indications and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a dose of 2 mg\/kg every three weeks.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with metastatic<br \/>\n      non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as<br \/>\n      determined by an FDA-approved test with disease progression on or after<br \/>\n      platinum-containing chemotherapy, at a dose of 2 mg\/kg every three<br \/>\n      weeks. Patients with EGFR or ALK genomic tumor aberrations should have<br \/>\n      disease progression on FDA-approved therapy for these aberrations prior<br \/>\n      to receiving KEYTRUDA. This indication is approved under accelerated<br \/>\n      approval based on tumor response rate and durability of response. An<br \/>\n      improvement in survival or disease-related symptoms has not yet been<br \/>\n      established. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy at a fixed dose<br \/>\n      of 200 mg every three weeks. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and durability of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      Immune-mediated pneumonitis, including fatal cases, occurred in patients<br \/>\n      receiving KEYTRUDA. Pneumonitis occurred in 32 (2.0%) of 1567 patients<br \/>\n      with melanoma, including Grade 1 (0.8%), 2 (0.8%), and 3 (0.4%)<br \/>\n      pneumonitis. Pneumonitis occurred in 19 (3.5%) of 550 patients with<br \/>\n      NSCLC, including Grade 2 (1.1%), 3 (1.3%), 4 (0.4%), or 5 (0.2%)<br \/>\n      pneumonitis and more frequently in patients with a history of<br \/>\n      asthma\/chronic obstructive pulmonary disease (5.4%) or prior thoracic<br \/>\n      radiation (6.0%). Monitor patients for signs and symptoms of<br \/>\n      pneumonitis. Evaluate suspected pneumonitis with radiographic imaging.<br \/>\n      Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold<br \/>\n      KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA (pembrolizumab)<br \/>\n      for Grade 3 or 4 or recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      Immune-mediated colitis occurred in 31 (2%) of 1567 patients with<br \/>\n      melanoma, including Grade 2 (0.5%), 3 (1.1%), and 4 (0.1%) colitis.<br \/>\n      Immune-mediated colitis occurred in 4 (0.7%) of 550 patients with NSCLC,<br \/>\n      including Grade 2 (0.2%) or 3 (0.4%) colitis. Monitor patients for signs<br \/>\n      and symptoms of colitis. Administer corticosteroids for Grade 2 or<br \/>\n      greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Immune-mediated hepatitis occurred in patients receiving KEYTRUDA.<br \/>\n      Hepatitis occurred in 16 (1%) of 1567 patients with melanoma, including<br \/>\n      Grade 2 (0.1%), 3 (0.7%), and 4 (0.1%) hepatitis. Monitor patients for<br \/>\n      changes in liver function. Administer corticosteroids for Grade 2 or<br \/>\n      greater hepatitis and, based on severity of liver enzyme elevations,<br \/>\n      withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 13 (0.8%) of 1567 patients with melanoma,<br \/>\n      including Grade 2 (0.3%), 3 (0.3%), and 4 (0.1%) hypophysitis.<br \/>\n      Hypophysitis occurred in 1 (0.2 %) of 550 patients with NSCLC, which was<br \/>\n      Grade 3 in severity. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 51 (3.3%) of 1567 patients with melanoma,<br \/>\n      including Grade 2 (0.6%) and 3 (0.1%) hyperthyroidism. Hypothyroidism<br \/>\n      occurred in 127 (8.1%) of 1567 patients with melanoma, including Grade 3<br \/>\n      (0.1%) hypothyroidism. Hyperthyroidism occurred in 10 (1.8%) of 550<br \/>\n      patients with NSCLC, including Grade 2 (0.7%) or 3 (0.3%)<br \/>\n      hyperthyroidism. Hypothyroidism occurred in 38 (6.9%) of 550 patients<br \/>\n      with NSCLC, including Grade 2 (5.5%) or 3 (0.2%) hypothyroidism. New or<br \/>\n      worsening hypothyroidism occurred in 28 (14.6%) of 192 patients with<br \/>\n      HNSCC, including Grade 3 (0.5%) hypothyroidism. Thyroid disorders can<br \/>\n      occur at any time during treatment. Monitor patients for changes in<br \/>\n      thyroid function (at the start of treatment, periodically during<br \/>\n      treatment, and as indicated based on clinical evaluation) and for<br \/>\n      clinical signs and symptoms of thyroid disorders. Administer replacement<br \/>\n      hormones for hypothyroidism and manage hyperthyroidism with thionamides<br \/>\n      and beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, occurred in 3<br \/>\n      (0.1%) of 2117 patients. Monitor patients for hyperglycemia or other<br \/>\n      signs and symptoms of diabetes. Administer insulin for type 1 diabetes,<br \/>\n      and withhold KEYTRUDA and administer anti-hyperglycemics in patients<br \/>\n      with severe hyperglycemia.\n    <\/p>\n<p>\n      Immune-mediated nephritis occurred in patients receiving KEYTRUDA<br \/>\n      (pembrolizumab). Nephritis occurred in 7 (0.4%) of 1567 patients with<br \/>\n      melanoma including, Grade 2 (0.2%), 3 (0.2%), and 4 (0.1%) nephritis.<br \/>\n      Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less<br \/>\n      following corticosteroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      Grade 3 immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 1567 patients<br \/>\n      with melanoma: arthritis (1.6%), exfoliative dermatitis, bullous<br \/>\n      pemphigoid, uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures<br \/>\n      arising in a patient with inflammatory foci in brain parenchyma. The<br \/>\n      following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of 550 patients with NSCLC: rash, vasculitis,<br \/>\n      hemolytic anemia, serum sickness, and myasthenia gravis.\n    <\/p>\n<p>\n      Severe and life-threatening infusion-related reactions have been<br \/>\n      reported in 3 (0.1%) of 2117 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n      hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and<br \/>\n      cardiac failure (0.4%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA (pembrolizumab) occurred in 21% of patients; the most common<br \/>\n      (\u22651%) was diarrhea (2.5%). The most common adverse reactions with<br \/>\n      KEYTRUDA vs ipilimumab were fatigue (28% vs 28%), diarrhea (26% with<br \/>\n      KEYTRUDA), rash (24% vs 23%), and nausea (21% with KEYTRUDA).<br \/>\n      Corresponding incidence rates are listed for ipilimumab only for those<br \/>\n      adverse reactions that occurred at the same or lower rate than with<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-002, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      12% of 357 patients with advanced melanoma; the most common (\u22651%) were<br \/>\n      general physical health deterioration (1%), asthenia (1%), dyspnea (1%),<br \/>\n      pneumonitis (1%), and generalized edema (1%). Adverse reactions leading<br \/>\n      to interruption of KEYTRUDA occurred in 14% of patients; the most common<br \/>\n      (\u22651%) were dyspnea (1%), diarrhea (1%), and maculopapular rash (1%). The<br \/>\n      most common adverse reactions with KEYTRUDA vs chemotherapy were fatigue<br \/>\n      (43% with KEYTRUDA), pruritus (28% vs 8%), rash (24% vs 8%),<br \/>\n      constipation (22% vs 20%), nausea (22% with KEYTRUDA), diarrhea (20% vs<br \/>\n      20%), and decreased appetite (20% with KEYTRUDA). Corresponding<br \/>\n      incidence rates are listed for chemotherapy only for those adverse<br \/>\n      reactions that occurred at the same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 14% of 550<br \/>\n      patients with NSCLC. Serious adverse reactions occurred in 38% of<br \/>\n      patients. The most frequent serious adverse reactions reported in at<br \/>\n      least 2% of patients were pleural effusion, pneumonia, dyspnea,<br \/>\n      pulmonary embolism, and pneumonitis. The most common adverse reactions<br \/>\n      (reported in at least 20% of patients) were fatigue (44%), cough (29%),<br \/>\n      decreased appetite (25%), and dyspnea (23%).\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 17% of 192<br \/>\n      patients with HNSCC. Serious adverse reactions occurred in 45% of<br \/>\n      patients. The most frequent serious adverse reactions reported in at<br \/>\n      least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (reported in at least 20% of patients) were fatigue<br \/>\n      (46%), decreased appetite (22%), and dyspnea (20%).\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment. Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 350 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51435301&amp;newsitemid=20161007005842&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=7c07a1b5e611aa4da537d055d52a3803\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51435301&amp;newsitemid=20161007005842&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=540c020bb82d454f54ed38ac2e637336\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51435301&amp;newsitemid=20161007005842&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=23426b861db21bdd162f52b75072488c\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51435301&amp;newsitemid=20161007005842&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=c79c069cee947bf6c6c4664a5d044fd1\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51435301&amp;newsitemid=20161007005842&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=bb11cfdea5d4a61bce891132cce5a17a\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51435301&amp;newsitemid=20161007005842&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=85c5ea9048bb3ff91b3540a3c1e4fdd9\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51435301&amp;newsitemid=20161007005842&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=5df7e14af7534c88f19409457b5a876f\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51435301&amp;newsitemid=20161007005842&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=8&amp;md5=53e6ebfc71e1e807f749a2db6c93bf50\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51435301&amp;newsitemid=20161007005842&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=bdc2269265346e8bc08ca210ca7bde95\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20161007005842r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Kim        Hamilton, 908-740-1863<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive findings from the phase 2 KEYNOTE-052 study investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in previously untreated patients with unresectable (inoperable) or metastatic urothelial cancer who are ineligible for cisplatin-based therapy. Data presented at the ESMO 2016 Congress, the annual meeting of the European Society for Medical Oncology, showed an overall response rate (ORR) of 24 percent (n=24\/100) (95% CI, 16-34) in the total study population, which included patients with and without PD-L1 expression. \u201cWe have a growing body of evidence of KEYTRUDA\u2019s activity in a range of cancers and treatment settings including the first-line treatment of patients with advanced urothelial cancer who will not tolerate cisplatin-based therapy,\u201d said Dr. Roger Dansey, senior vice president, oncology late-stage development, Merck Research Laboratories. The KEYTRUDA<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289,56],"class_list":["post-745322","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New KEYTRUDA\u00ae (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-in-advanced-urothelial-cancer-demonstrate-overall-response-rate-of-24-percent-in-cisplatin-ineligible-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New KEYTRUDA\u00ae (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive findings from the phase 2 KEYNOTE-052 study investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in previously untreated patients with unresectable (inoperable) or metastatic urothelial cancer who are ineligible for cisplatin-based therapy. Data presented at the ESMO 2016 Congress, the annual meeting of the European Society for Medical Oncology, showed an overall response rate (ORR) of 24 percent (n=24\/100) (95% CI, 16-34) in the total study population, which included patients with and without PD-L1 expression. \u201cWe have a growing body of evidence of KEYTRUDA\u2019s activity in a range of cancers and treatment settings including the first-line treatment of patients with advanced urothelial cancer who will not tolerate cisplatin-based therapy,\u201d said Dr. Roger Dansey, senior vice president, oncology late-stage development, Merck Research Laboratories. The KEYTRUDA\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-in-advanced-urothelial-cancer-demonstrate-overall-response-rate-of-24-percent-in-cisplatin-ineligible-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-keytruda-pembrolizumab-data-in-advanced-urothelial-cancer-demonstrate-overall-response-rate-of-24-percent-in-cisplatin-ineligible-patients\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-keytruda-pembrolizumab-data-in-advanced-urothelial-cancer-demonstrate-overall-response-rate-of-24-percent-in-cisplatin-ineligible-patients\\\/\",\"name\":\"New KEYTRUDA\u00ae (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-10-08T01:15:00+00:00\",\"dateModified\":\"2025-11-07T06:25:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-keytruda-pembrolizumab-data-in-advanced-urothelial-cancer-demonstrate-overall-response-rate-of-24-percent-in-cisplatin-ineligible-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-keytruda-pembrolizumab-data-in-advanced-urothelial-cancer-demonstrate-overall-response-rate-of-24-percent-in-cisplatin-ineligible-patients\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-keytruda-pembrolizumab-data-in-advanced-urothelial-cancer-demonstrate-overall-response-rate-of-24-percent-in-cisplatin-ineligible-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New KEYTRUDA\u00ae (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New KEYTRUDA\u00ae (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-in-advanced-urothelial-cancer-demonstrate-overall-response-rate-of-24-percent-in-cisplatin-ineligible-patients\/","og_locale":"en_US","og_type":"article","og_title":"New KEYTRUDA\u00ae (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive findings from the phase 2 KEYNOTE-052 study investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in previously untreated patients with unresectable (inoperable) or metastatic urothelial cancer who are ineligible for cisplatin-based therapy. Data presented at the ESMO 2016 Congress, the annual meeting of the European Society for Medical Oncology, showed an overall response rate (ORR) of 24 percent (n=24\/100) (95% CI, 16-34) in the total study population, which included patients with and without PD-L1 expression. \u201cWe have a growing body of evidence of KEYTRUDA\u2019s activity in a range of cancers and treatment settings including the first-line treatment of patients with advanced urothelial cancer who will not tolerate cisplatin-based therapy,\u201d said Dr. Roger Dansey, senior vice president, oncology late-stage development, Merck Research Laboratories. The KEYTRUDA","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-in-advanced-urothelial-cancer-demonstrate-overall-response-rate-of-24-percent-in-cisplatin-ineligible-patients\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:38+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-in-advanced-urothelial-cancer-demonstrate-overall-response-rate-of-24-percent-in-cisplatin-ineligible-patients\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-in-advanced-urothelial-cancer-demonstrate-overall-response-rate-of-24-percent-in-cisplatin-ineligible-patients\/","name":"New KEYTRUDA\u00ae (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-10-08T01:15:00+00:00","dateModified":"2025-11-07T06:25:38+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-in-advanced-urothelial-cancer-demonstrate-overall-response-rate-of-24-percent-in-cisplatin-ineligible-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-in-advanced-urothelial-cancer-demonstrate-overall-response-rate-of-24-percent-in-cisplatin-ineligible-patients\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-keytruda-pembrolizumab-data-in-advanced-urothelial-cancer-demonstrate-overall-response-rate-of-24-percent-in-cisplatin-ineligible-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"New KEYTRUDA\u00ae (pembrolizumab) Data in Advanced Urothelial Cancer Demonstrate Overall Response Rate of 24 Percent in Cisplatin-Ineligible Patients"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"39bcdeb8-0ebc-450e-ad04-e6f0c4b37276","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/New-KEYTRUDA-pembrolizumab-Data-in-Advanced-Urothelial-Cancer-Demonstrate-Overall-Response-Rate-of-24-Percent-in-Cisplatin-Ineligible-UVLQO.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745322","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745322\/revisions"}],"predecessor-version":[{"id":3674729,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745322\/revisions\/3674729"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745322"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745322"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}